Phosphono-carboxylate compounds for treating amyloidosis
First Claim
1. A method for modulating amyloid deposition in a subject, comprising administering to a subject an effective amount of a therapeutic compound such that modulation of amyloid deposition occurs, wherein the therapeutic compound has the formula:
-
in which R1 and R2 are each independently hydrogen, a substituted or unsubstituted aliphatic group, an aryl group, a heterocyclic group, or a salt-forming cation;
R3 is hydrogen, lower alkyl, aryl, or a salt-forming cation;
R4 is hydrogen, lower alkyl, aryl or amino;
X is, independently for each occurrence, O or S;
Y1 and Y2 are each independently hydrogen, halogen, alkyl, amino, hydroxy, alkoxy, or aryloxy;
Z is XR2 or R4; and
n is an integer from 0 to 12.
1 Assignment
0 Petitions
Accused Products
Abstract
Therapeutic compounds and methods for modulating amyloid deposition in a subject, whatever its clinical setting, are described. Amyloid deposition is modulated by the administration to a subject of an effective amount of a therapeutic compound comprising a phosphonate group and a carboxylate group, a congener thereof, or a pharmaceutically acceptable salt or ester thereof. In preferred embodiments, an interaction between an amyloidogenic protein and a basement membrane constituent is modulated.
-
Citations
1 Claim
-
1. A method for modulating amyloid deposition in a subject, comprising administering to a subject an effective amount of a therapeutic compound such that modulation of amyloid deposition occurs, wherein the therapeutic compound has the formula:
-
in which R1 and R2 are each independently hydrogen, a substituted or unsubstituted aliphatic group, an aryl group, a heterocyclic group, or a salt-forming cation;
R3 is hydrogen, lower alkyl, aryl, or a salt-forming cation;
R4 is hydrogen, lower alkyl, aryl or amino;
X is, independently for each occurrence, O or S;
Y1 and Y2 are each independently hydrogen, halogen, alkyl, amino, hydroxy, alkoxy, or aryloxy;
Z is XR2 or R4; and
n is an integer from 0 to 12.
-
Specification
-
- Resources
-
Current AssigneeNeurochem (International) Limited (GSK plc)
-
Original AssigneeNeurochem (International) Limited (GSK plc)
-
InventorsKong, Xianqi, Szarek, Walter A., Thatcher, Gregory R.J., Gorine, Boris
-
Application NumberUS11/246,888Publication NumberTime in Patent OfficeDaysField of SearchUS Class Current514/79CPC Class CodesA61K 31/66 Phosphorus compoundsA61K 31/662 Phosphorus acids or esters ...A61K 31/675 having nitrogen as a ring h...A61P 25/00 Drugs for disorders of the ...
